ESMO 2023 | CheckMate 7FL: nivo vs PBO in high-risk ER+ HER2- BC with neoadjuvant chemo and adjuvant therapy

Sherene Loi, MD, PhD, Peter MacCallum Cancer Centre, Victoria, Australia, discusses the results of the Phase III CHECKMATE-7FL (NCT04109066) trial of nivolumab plus neoadjuvant chemotherapy versus placebo in patients with high-risk, ER-positive, HER2-negative primary breast cancer. The trial included newly diagnosed patients with specific tumor characteristics and was initially randomized. In the modified analysis, nivolumab plus neoadjuvant chemotherapy significantly increased the pathological complete response (pCR) rate compared to neoadjuvant chemotherapy alone, with greater benefits in stage III and PD-L1+ patients. Adverse events were observed, with a higher incidence of immune-mediated adverse events in the nivolumab group. Overall, this approach met its primary endpoint with improved pCR and RCB 0-1 rates, especially in PD-L1+ patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.